TickerTalks
Browse all tickers →
TickerTalks›$BFLY
BFBFLY

Butterfly Network, Inc.

$BFLY·$2.2B·Medical - Devices·Healthcare
$7.25-7.6%YTD+102.3%1Y+223.7%
Price updated 7h ago·X counts updated 5d ago
BFBFLY
$BFLYButterfly Network, Inc.
$7.25-7.64%203 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $BFLY on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

203X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $BFLY's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 55% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-31

Sentiment is quietly bullish and technically-driven — several traders flag a two-month cup-and-handle setup on Butterfly Network, note fresh positions started in the low $8s, and frame the name as part of a broader AI-in-medical-devices thesis alongside ABSI, IMNM, and ABCL. The chatter is thin but coherent, and no bearish counter-argument surfaces in the sample.

Read what X is saying about $BFLY

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $BFLY — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

Pocket ultrasound-on-chip up ~4.5x TTM on the AI-med-devices narrative — still unprofitable, but the top line is finally following.

Butterfly Network makes the handheld ultrasound-on-chip — the iQ+ device that puts a diagnostic imaging probe in a doctor's pocket. The stock has 4.5x'd TTM as the AI-in-medical-devices narrative caught up with the hardware story.

  • Revenue is accelerating off a small base: Q1 2026 of $26.5M at +25% YoY after Q4 2025 at +41% — the handheld-ultrasound category is finally scaling, with the Mendaera system integration adding a credible channel partner.
  • The P&L is still red: operating margin of -51% on 69% gross margin means the equity trades on the growth story, not operating economics — consensus has 2028 EPS swinging barely positive at $0.01.
  • Glenview Capital (4.8%) and founder Rothberg (0.3%) are both reporting unchanged positions in SC 13D/A filings — the structural ownership is intact, though insider sales from CTO Cashman ($1.02M on Sep 4) are the near-term counter.

Oct 30 Q3 earnings with revenue above $28M and gross margin above 65% extends the move; a weak growth print or further C-suite selling and the +131% YTD gives back easily.

Agrees with X sentimentX is bullish on the AI-in-medical-devices thesis (grouped with ABSI, IMNM, ABCL) and the cup-and-handle setup in the low $8s — directionally real and the recent analyst upgrade plus Mendaera partnership back it. The crowd under-weights the ongoing C-suite selling that doesn't quite support a secular bullish thesis.

What to watch: Oct 30 Q3 earnings — revenue above $28M, probe-sales growth above 25% YoY, and gross-margin trend above 65%. Any softening in device unit growth or another CTO/CFO sale and the +131% YTD unwinds; a clean beat sustains the move.

On the calendar: 2026-10-30 — Q3 2026 earnings

Read the AI verdict on $BFLY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes a chip-scale portable ultrasound probe (iQ+) pairing with smartphones for point-of-care whole-body imaging.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $BFLY.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $BFLY

Neutral — Makes a chip-scale portable ultrasound probe (iQ+) pairing with smartphones for point-of-care whole-body imaging.

Industry benchmark

21-name peer basket
+5.2%YTD
-10.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-30.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-35.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-79.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
22.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-36.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
49.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$-0.01$-0.04+71.4%
Q1 2026Apr 30, 2026$-0.03$-0.04+25.0%
Q4 2025Feb 26, 2026$-0.02$-0.04+50.0%
Q3 2025Oct 31, 2025$-0.13$-0.07-85.7%
Next earningsThu, Oct 29·consensus EPS $-0.04

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$26.5M+25.0%68.9%-50.8%$-0.05$-14.8M
Q4 FY25$31.5M+41.0%67.3%-61.8%$-0.06$7.9M
Q3 FY25$21.5M+4.5%-17.5%-151%$-0.13$-3.9M
Q2 FY25$23.4M+8.8%63.7%-68.9%$-0.06$-8.1M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$121.6M$118.1M – $126.6M-$0.11-$0.12 – -$0.114
FY27$149.3M$145.0M – $155.4M-$0.07-$0.07 – -$0.074
FY28$196.6M$181.3M – $216.9M$0.01$0.00 – $0.034
FY29$312.3M$303.3M – $325.1M$0.66$0.64 – $0.702
FY30$550.0M$534.1M – $572.6M$0.58$0.56 – $0.612

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.64%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+23.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 216.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.045-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 6Joseph DevivoCEO35.8K sh$359KSellOct 2Megan CarlsonCAO and SVP, Finance10.1K sh$88KSellSep 23Joseph DevivoCEO3.2K sh$32KSellSep 22Joseph DevivoCEO2.8K sh$28KSellSep 4Steve CashmanChief Business Officer140.1K sh$1.0MSellSep 4Megan CarlsonCAO and SVP, Finance13.8K sh$101KSellSep 2Nicholas CaezzaDeputy General Counsel1.7K sh$14KSellAug 17Larry RobbinsDirector582.5K sh$5.2MBuyAug 14Phanstiel S. LouiseDirector115.2K sh$1000KSellAug 14Larry RobbinsDirector824.7K sh$7.2M
1–10 of 35
+ 9 other (8 awards · 1 gift) in window

See when $BFLY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsOct 153
8-KOfficer or director changeOct 58-K — Item 5.02: Officer or director change
SC 13D/AActivist amendmentAug 17SC 13D/A
AI summary

Glenview Capital Management (Larry Robbins) filed SC 13D Amendment No. 8 for Butterfly Network, Inc., triggered August 13, 2026. Glenview Capital holds 11,743,530 Class A shares (4.8% of 244,858,246 shares outstanding); including shares held by Longview Investors LLC (2,964,187) and personal direct holdings, Robbins' aggregate is 15,120,314 shares (6.17%). Ongoing engaged investor position update for Glenview, one of Butterfly Network's significant holders, with no stated change in intent.

SC 13D/AActivist amendmentAug 17SC 13D/A
AI summary

Jonathan M. Rothberg, Ph.D. (Butterfly Network founder) filed SC 13D Amendment No. 12, triggered August 14, 2026. For Class A shares, Rothberg holds 828,775 shares (0.3% of 244,858,246 outstanding), including 80,434 direct plus 726,696 held by his spouse and 21,645 options exercisable within 60 days. For Class B shares, Rothberg holds sole control of all 21,426,937 outstanding shares (100%) via 4C Holdings entities. The dual-class structure means Rothberg retains significant voting control through his Class B position despite a modest economic interest in Class A. Routine update with no stated change in intent.

8-KOfficer or director changeAug 118-K — Item 5.02: Officer or director change
AI summary

Butterfly Network (BFLY) disclosed that Dr. Erica Schwartz has been confirmed as Director of the Centers for Disease Control and Prevention, triggering her previously announced board resignation. The Board has a resulting vacancy following her confirmation to this government role.

SC 13D/AActivist amendmentJul 21SC 13D/A
AI summary

Jonathan M. Rothberg filed Amendment No. 11 to his Schedule 13D on Butterfly Network, Inc. on July 21, 2026, disclosing he beneficially owns approximately 828,775 shares of Class A common stock (~0.4% of Class A, out of 234.8 million shares outstanding) and 22,086,850 shares of Class B common stock (100% of Class B), held through 4C Holdings entities and family trusts. No new acquisition or disposition is highlighted as the triggering event in the excerpt. As the sole holder of all Class B shares — which likely carry supervoting rights — Rothberg retains effective voting control of the company; this amendment appears to be a routine update to position details rather than a new activist or strategic move.

SC 13D/AActivist amendmentJul 17SC 13D/A
AI summary

Jonathan Rothberg, founder of Butterfly Network, filed Amendment 10 to his Schedule 13D disclosing current beneficial ownership of 828,775 shares, approximately 0.4% of outstanding stock. This represents a substantial reduction from his prior reported position, reflecting sales or dilution from company share issuances over time.

8-KShareholder voteJun 228-K — Item 5.07: Shareholder vote
AI summary

Butterfly Network, Inc. held its 2026 Annual Meeting on June 18, 2026, with 163.2M Class A and 26.4M Class B shares voting as a single class (Class B carries 20 votes per share). All seven director nominees were re-elected for one-year terms: Joseph DeVivo (621.7M votes), Jonathan Rothberg Ph.D. (622.4M), Larry Robbins (622.1M), Caroll Neubauer (622.5M), Elazer Edelman M.D. (622.2M), S. Louise Phanstiel (622.0M), and Erica Schwartz M.D. (621.8M). Two additional proposals were voted on (details truncated). Routine annual governance meeting for a medical ultrasound imaging technology company.

+ 12 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

The Edward Via College of Osteopathic Medicine (VCOM) and Butterfly Network Announce Long-Term Alliance to Build New Model for Ultrasound Educationbusinesswire.com·4d agoButterfly Network (NYSE:BFLY) Shares Up 6.6% – Here’s What Happeneddefenseworld.net·6d agoBeyond Elon Musk's Neuralink: Two Public Stocks With a Stake in the Brain Raceinvestorplace.com·7d ago2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Privateinvestorplace.com·8d agoButterfly Network to Report Third Quarter 2026 Financial Results on October 29, 2026businesswire.com·9d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$MDT$QSI$BIO$ABT$PACB$BSX$GEHC
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport